Berkshire Asset Management’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $281K | Sell |
1,534
-1
| -0.1% | -$184 | 0.01% | 223 |
|
|
2025
Q4 | $270K | Sell |
1,535
-6
| -0.4% | -$980 | 0.01% | 228 |
|
|
2025
Q3 | $216K | Buy |
+1,541
| New | +$208K | 0.01% | 279 |
|
|
2025
Q1 | – | Sell |
-1,568
| Closed | -$229K | – | 283 |
|
|
2024
Q4 | $229K | Sell |
1,568
-461
| -23% | -$77.8K | 0.01% | 258 |
|
|
2024
Q3 | $470K | Hold |
2,029
| – | – | 0.02% | 190 |
|
|
2024
Q2 | $470K | Sell |
2,029
-38
| -2% | -$8.26K | 0.02% | 191 |
|
|
2024
Q1 | $446K | Sell |
2,067
-10
| -0.5% | -$2.34K | 0.02% | 172 |
|
|
2023
Q4 | $537K | Sell |
2,077
-33
| -2% | -$8.11K | 0.03% | 147 |
|
|
2023
Q3 | $542K | Sell |
2,110
-94
| -4% | -$25.1K | 0.03% | 141 |
|
|
2023
Q2 | $628K | Sell |
2,204
-325
| -13% | -$96.7K | 0.04% | 131 |
|
|
2023
Q1 | $703K | Buy |
+2,529
| New | +$700K | 0.04% | 127 |
|
|
2022
Q4 | – | Sell |
-2,352
| Closed | -$628K | – | 150 |
|
|
2022
Q3 | $628K | Sell |
2,352
-445
| -16% | -$94.5K | 0.04% | 125 |
|
|
2022
Q2 | $570K | Sell |
2,797
-825
| -23% | -$169K | 0.04% | 132 |
|
|
2022
Q1 | $763K | Buy |
3,622
+60
| +2% | +$13K | 0.05% | 110 |
|
|
2021
Q4 | $855K | Sell |
3,562
-1,928
| -35% | -$496K | 0.05% | 127 |
|
|
2021
Q3 | $1.55M | Sell |
5,490
-78
| -1% | -$25.6K | 0.1% | 100 |
|
|
2021
Q2 | $1.93M | Sell |
5,568
-285
| -5% | -$86.3K | 0.13% | 87 |
|
|
2021
Q1 | $1.64M | Buy |
5,853
+341
| +6% | +$92K | 0.12% | 87 |
|
|
2020
Q4 | $1.35M | Buy |
5,512
+3,331
| +153% | +$859K | 0.1% | 98 |
|
|
2020
Q3 | $619K | Sell |
2,181
-112
| -5% | -$31.2K | 0.06% | 107 |
|
|
2020
Q2 | $613K | Sell |
2,293
-3,141
| -58% | -$944K | 0.06% | 106 |
|
|
2020
Q1 | $1.72M | Buy |
5,434
+3,210
| +144% | +$974K | 0.18% | 70 |
|
|
2019
Q4 | $660K | Buy |
2,224
+67
| +3% | +$18.6K | 0.06% | 112 |
|
|
2019
Q3 | $502K | Sell |
2,157
-113
| -5% | -$26.3K | 0.04% | 138 |
|
|
2019
Q2 | $531K | Buy |
2,270
+258
| +13% | +$59.6K | 0.04% | 131 |
|
|
2019
Q1 | $476K | Buy |
2,012
+10
| +0.5% | +$3.15K | 0.04% | 147 |
|
|
2018
Q4 | $602K | Sell |
2,002
-145
| -7% | -$46.3K | 0.06% | 129 |
|
|
2018
Q3 | $759K | Buy |
2,147
+12
| +0.6% | +$4.13K | 0.06% | 125 |
|
|
2018
Q2 | $620K | Buy |
2,135
+329
| +18% | +$92.5K | 0.06% | 126 |
|
|
2018
Q1 | $495K | Sell |
1,806
-64
| -3% | -$19.9K | 0.05% | 138 |
|
|
2017
Q4 | $596K | Buy |
1,870
+28
| +2% | +$8.98K | 0.06% | 127 |
|
|
2017
Q3 | $577K | Sell |
1,842
-125
| -6% | -$37K | 0.06% | 117 |
|
|
2017
Q2 | $534K | Sell |
1,967
-230
| -10% | -$60.8K | 0.06% | 121 |
|
|
2017
Q1 | $601K | Buy |
2,197
+189
| +9% | +$53.4K | 0.07% | 115 |
|
|
2016
Q4 | $569K | Sell |
2,008
-328
| -14% | -$97.2K | 0.07% | 114 |
|
|
2016
Q3 | $731K | Sell |
2,336
-1,427
| -38% | -$423K | 0.11% | 102 |
|
|
2016
Q2 | $910K | Buy |
3,763
+799
| +27% | +$211K | 0.14% | 90 |
|
|
2016
Q1 | $772K | Buy |
2,964
+68
| +2% | +$18K | 0.12% | 89 |
|
|
2015
Q4 | $887K | Buy |
2,896
+150
| +5% | +$43.1K | 0.15% | 86 |
|
|
2015
Q3 | $801K | Buy |
2,746
+869
| +46% | +$287K | 0.14% | 89 |
|
|
2015
Q2 | $758K | Sell |
1,877
-33
| -2% | -$13.2K | 0.13% | 93 |
|
|
2015
Q1 | $806K | Sell |
1,910
-266
| -12% | -$105K | 0.13% | 92 |
|
|
2014
Q4 | $739K | Buy |
2,176
+43
| +2% | +$13.9K | 0.13% | 94 |
|
|
2014
Q3 | $706K | Hold |
2,133
| – | – | 0.13% | 96 |
|
|
2014
Q2 | $673K | Hold |
2,133
| – | – | 0.12% | 94 |
|
|
2014
Q1 | $652K | Sell |
2,133
-3,935
| -65% | -$1.25M | 0.13% | 91 |
|
|
2013
Q4 | $1.7M | Buy |
6,068
+850
| +16% | +$220K | 0.32% | 66 |
|
|
2013
Q3 | $1.26M | Buy |
5,218
+3,505
| +205% | +$784K | 0.3% | 73 |
|
|
2013
Q2 | $369K | Buy |
+1,713
| New | +$366K | 0.1% | 95 |
|
Other funds holding BIIB
VCM
VPM
Berkshire Asset Management's BIIB Position: Q1 2026 in Review
Berkshire Asset Management reduced its Biogen (BIIB) stake by 0.07% in Q1 2026, selling an estimated $184 and leaving 1,534 shares worth $281K. The position accounts for 0.01% of the portfolio, ranked #223.
Berkshire Asset Management first reported a position in BIIB in Q2 2013 and has held it in 49 quarters since. The position peaked at $1.93M in Q2 2021. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Berkshire Asset Management held 1,534 shares of Biogen worth $281K as of Q1 2026.
- Berkshire Asset Management sold 1 Biogen share in Q1 2026, an estimated $184.
- Biogen made up 0.01% of Berkshire Asset Management's portfolio in Q1 2026, its #223 holding.
- Berkshire Asset Management first reported a position in Biogen in Q2 2013 and has held it in 49 quarters since.
- Berkshire Asset Management's Biogen position peaked at $1.93M in Q2 2021.
- 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Berkshire Asset Management's 13F filing for Q1 2026, filed 11 May 2026.